Sino BiologicalInc. (301047) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Sino BiologicalInc. ¥21.91, price ¥159, upside -86.2%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sino BiologicalInc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
60‑month range ¥50.24 – ¥270.93 · fair‑value band ¥15.10 – ¥28.54 · the ¥159.00 price screens above the ¥21.91 fair value. Dashed = 300-day average. As of Sep 28, 2026.
Follow Sino BiologicalInc. in your weekly email
Every Wednesday you see whether Sino BiologicalInc. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents.
Show more
Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies. Sino Biological,Inc. was founded in 2016 and is headquartered in Beijing, China.
Stock analysis
Sino BiologicalInc. (301047) currently trades at ¥159.00, while our model-based Fair Value estimate is ¥21.91, 86.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ¥63.94 per share, and 0 of the 26 models we run sit above the ¥159.00 price.
Bear case: the Economic Profit group reads lowest at ¥8.81, and 26 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥15.10 (bear) to ¥28.54 (bull), the price of ¥159.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Sino BiologicalInc. reported revenue of 700M CNY in FY2025 versus 965M CNY in FY2021, a compound −7.7%/yr. Reported net income was 148M CNY in FY2025, compounding −32.7%/yr from FY2021.
Key figures
Market cap 7.2B CNY (≈ $1.1B) · P/E ratio 46.1 · P/S ratio 9.74 · EPS (TTM) ¥1.29 · Dividend yield 3.3% · Net margin 21.1% · Return on equity 2.8% · Return on assets (EBIT) 4.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 169% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −86%, 301047 screens richer than that median.
Fair Value models
Bear ¥15.10Fair Value ¥21.91Bull ¥28.54
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+14.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.3%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−29.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.3%
Dividend (yield on the price)3.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.85% → 15%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+79.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +76.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside−86.2% · Bottom 25%
Profitability
Return on equity (TTM)2.8% · Above median
Return on assets1.2% · Above median
Net margin (TTM)21.6% · Top 25%
Operating margin (TTM)17.5% · Top 25%
Growth and dividend
Revenue growth18.1% · Above median
Dividend yield (TTM)3.3% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)46.1× · Pricier than median
P/B1.36× · Cheaper than median
P/S (TTM)9.94× · Pricier than median
P/FCF160.2× · Priciest 25%
EV/EBITDA39.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)91· sector 0
PAST (return on equity)11· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)65· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sino BiologicalInc. Fair Value". https://www.fairvalue-calculator.com/stock/301047
Frequently asked questions
Is Sino BiologicalInc. (301047) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of ¥21.91 versus a price of ¥159.00, about −86% upside (overvalued).
What is the fair value of 301047?
Our model-based fair value for Sino BiologicalInc. is ¥21.91 (as of Sep 28, 2026), built from audited fundamentals. The current price: ¥159.00.
What is the quality score of 301047?
Sino BiologicalInc. has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sino BiologicalInc. (301047)?
Our model-based price target is the fair value of ¥21.91 (as of Sep 28, 2026) from 26 valuation models. Cautious scenario ¥15.10, optimistic scenario ¥28.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Sino BiologicalInc. stock forecast for 2026?
Our models put fair value at ¥21.91, about −86% upside versus a price of ¥159.00 (overvalued). Cautious scenario ¥15.10, optimistic scenario ¥28.54. The calculation is refreshed regularly with new filings.
What is the revenue of Sino BiologicalInc. (301047)?
Sino BiologicalInc. reported trailing-twelve-month revenue of about 728M CNY (latest available figure, as of Sep 28, 2026).
Does Sino BiologicalInc. pay a dividend?
Sino BiologicalInc. currently shows a dividend yield of about 3.27% relative to its recent price (as of Sep 28, 2026).
What growth is priced into Sino BiologicalInc. (301047)?
For today's price to be fair in a discounted-cash-flow model, Sino BiologicalInc. would have to grow free cash flow by +79.1 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -15.2 % per year. As of Sep 28, 2026.
What discount rate (WACC) does the fair value of 301047 use?
Our models discount Sino BiologicalInc. at 11.1 %: a base by market capitalisation (small), damped by beta 0.72, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sino BiologicalInc. that is +79.1 % per year a year over ten years, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Sino BiologicalInc. (301047) delivered so far?
Over the past 5 years revenue at Sino BiologicalInc. grew -15.2 % a year. The price currently implies +79.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sino BiologicalInc. (301047) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Sino BiologicalInc. (+79.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sino BiologicalInc. (301047)?
The free-cash-flow yield on the price is 0.23 %: that much free cash flow Sino BiologicalInc. produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sino BiologicalInc. (301047)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sino BiologicalInc. it is ¥21.91 per share (as of Sep 28, 2026), against a price of ¥159.00. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sino BiologicalInc. stock overvalued or undervalued in 2026?
As of Sep 28, 2026, 301047 trades above its calculated fair value: price ¥159.00, fair value ¥21.91, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301047?
No. The price is what the market pays today (¥159.00); the fair value is what the company's own numbers justify (¥21.91). For Sino BiologicalInc. the two are ¥137.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sino BiologicalInc. worth?
The market values Sino BiologicalInc. at about 7.2B CNY (market capitalisation, as of Sep 28, 2026). Per share that is ¥159.00; our models calculate a fair value of ¥21.91 per share.
What do the bullish and bearish scenarios say about 301047?
Our models span a range for Sino BiologicalInc.: cautious scenario ¥15.10, base ¥21.91, optimistic ¥28.54 per share (as of Sep 28, 2026, price ¥159.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301047?
Sino BiologicalInc. trades at a price-to-earnings ratio of 46.1 (as of Sep 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥21.91 is built from several models across several years. Other multiples: P/B 1.4, P/S 9.9, EV/EBITDA 39.6.
How solid is the balance sheet of Sino BiologicalInc. (301047)?
Balance-sheet figures for Sino BiologicalInc. (as of Sep 28, 2026): return on equity 2.8%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 301047 from its 52-week high?
Sino BiologicalInc. trades at ¥159.00, at its 52-week high of ¥159.00 and 169% above the low of ¥59.20 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥21.91 is for.
Which stocks are comparable to Sino BiologicalInc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sino BiologicalInc. stock attractive at the current price?
The data as of Sep 28, 2026: price ¥159.00, calculated fair value ¥21.91 (−86%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301047 calculated?
We run Sino BiologicalInc. through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥21.91, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sino BiologicalInc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sino BiologicalInc. (301047)?
The closing price on Sep 30, 2026 was ¥159.00. Our model-based fair value is ¥21.91, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sino BiologicalInc. right now?
The price sits above even our optimistic bull case (¥28.54). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥15.10 to ¥28.54) leaves room in how you read the outcome.
Key figures of Sino BiologicalInc.
How large is the market capitalisation of Sino BiologicalInc. (301047)?
The market capitalisation of Sino BiologicalInc. is 7.2B CNY (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sino BiologicalInc. (301047)?
The price-to-sales ratio of Sino BiologicalInc. is 9.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sino BiologicalInc. (301047)?
Earnings per share at Sino BiologicalInc. are ¥1.29 (price ÷ EPS = P/E 46.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sino BiologicalInc. (301047)?
The dividend yield of Sino BiologicalInc. is 3.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sino BiologicalInc. (301047)?
The net margin of Sino BiologicalInc. is 21.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sino BiologicalInc. (301047)?
The return on equity (ROE) of Sino BiologicalInc. is 2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sino BiologicalInc. (301047)?
On an EBIT basis the return on assets of Sino BiologicalInc. is 4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sino BiologicalInc. (301047)?
The operating margin of Sino BiologicalInc. is 17.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sino BiologicalInc. (301047)?
Revenue at Sino BiologicalInc. is growing +18.1% versus a year earlier (3y avg +6.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sino BiologicalInc. (301047)?
Earnings per share at Sino BiologicalInc. are growing +42.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Sino BiologicalInc. in the live analysis
One click puts Sino BiologicalInc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
